Mitomycin C
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-MITOMYCIN-C |
|---|---|
| Type | Drug |
| Aliases | Mitomycin |
| Status | reviewed 2026-05-07 |
| Diseases | DIS-ANAL-SCC |
| Sources | SRC-ACT2-JAMES-2013 SRC-NCCN-ANAL-2025 |
Drug Facts
| Class | Bioreductive alkylating antitumor antibiotic |
|---|---|
| Mechanism | Antitumor antibiotic that is enzymatically activated to alkylating species capable of DNA crosslinking. Used as the mitomycin component of definitive chemoradiation for anal squamous cell carcinoma. |
| Typical dosing | Anal SCC chemoradiation commonly uses mitomycin 10-12 mg/m2 IV on day 1 and day 29 with fluoropyrimidine-based radiation sensitization. Dose and omission rules are regimen-specific. |
| Ukraine registered | False |
| NSZU reimbursed | False |
Warnings
- Bone marrow suppression
- Hemolytic uremic syndrome
Notes
Thin drug entity added to resolve REG-NIGRO-MMC-5FU-RT component references. Detailed drug-label metadata should be expanded in the anal SCC curation pass.
Used By
Regimens
REG-NIGRO-MMC-5FU-RT- Nigro protocol (mitomycin-C + 5-FU + RT, anal SCC)